Apatinib-d8 free base

• CAT Number: S000451
• CAS Number: 2468771-43-7
• Molecular Formula: C24H15D8N5O
• Molecular Weight: 405.52
• Purity: ≥95%
• Target: Autophagy
• IUPAC Name: N-[4-(1-cyano-2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
• InChI: InChI=1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)/i1D2,2D2,11D2,12D2
• InChIKey: WPEWQEMJFLWMLV-MMBGVTJSSA-N
• SMILES: C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4

Apatinib-d8 free base（Cat No.:S000451） is a deuterated form of apatinib, where eight hydrogen atoms are replaced with deuterium. This modification is employed in research to examine the drug’s metabolic stability and pharmacokinetic properties more thoroughly. Apatinib is a tyrosine kinase inhibitor used primarily in the treatment of gastric cancer and other advanced solid tumors. It targets the vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting tumor angiogenesis which is the process of new blood vessel formation. The deuterated version, Apatinib-d8, provides deeper insights into the drug’s behavior and interactions within the body.